DK1509543T3 - Ikke-immunundertrykkende immunogen eller vaccinesammensætning, omfattende et muteret E7-protein fra virussen HPV-16 - Google Patents

Ikke-immunundertrykkende immunogen eller vaccinesammensætning, omfattende et muteret E7-protein fra virussen HPV-16

Info

Publication number
DK1509543T3
DK1509543T3 DK03747137T DK03747137T DK1509543T3 DK 1509543 T3 DK1509543 T3 DK 1509543T3 DK 03747137 T DK03747137 T DK 03747137T DK 03747137 T DK03747137 T DK 03747137T DK 1509543 T3 DK1509543 T3 DK 1509543T3
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
protein
hpv
mutated
Prior art date
Application number
DK03747137T
Other languages
Danish (da)
English (en)
Inventor
Buanec Helene Le
Bernard Bizzini
Daniel Zagury
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of DK1509543T3 publication Critical patent/DK1509543T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03747137T 2002-04-24 2003-04-04 Ikke-immunundertrykkende immunogen eller vaccinesammensætning, omfattende et muteret E7-protein fra virussen HPV-16 DK1509543T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0205173A FR2839072A1 (fr) 2002-04-24 2002-04-24 Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
PCT/FR2003/001082 WO2003090667A2 (fr) 2002-04-24 2003-04-04 Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16

Publications (1)

Publication Number Publication Date
DK1509543T3 true DK1509543T3 (da) 2008-12-15

Family

ID=28799908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03747137T DK1509543T3 (da) 2002-04-24 2003-04-04 Ikke-immunundertrykkende immunogen eller vaccinesammensætning, omfattende et muteret E7-protein fra virussen HPV-16

Country Status (13)

Country Link
US (1) US7314629B2 (de)
EP (1) EP1509543B1 (de)
JP (1) JP2005532298A (de)
CN (1) CN1656116A (de)
AT (1) ATE408620T1 (de)
AU (1) AU2003249143B2 (de)
BR (1) BR0309491A (de)
CA (1) CA2483819C (de)
DE (1) DE60323634D1 (de)
DK (1) DK1509543T3 (de)
ES (1) ES2312801T3 (de)
FR (1) FR2839072A1 (de)
WO (1) WO2003090667A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8452541B2 (en) * 2007-06-18 2013-05-28 Microsoft Corporation Vaccine design methodology
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP5146113B2 (ja) * 2008-05-30 2013-02-20 住友電装株式会社 電気接続箱
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010148496A1 (en) * 2009-06-22 2010-12-29 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
CN105177047B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用
CN105177048B (zh) * 2014-08-12 2018-02-02 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用
CN114075293B (zh) * 2020-08-14 2022-11-15 长沙诺盟生物医药有限公司 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DK1108035T3 (da) * 1998-09-04 2007-09-24 Sanofi Pasteur Ltd Behandling af cervixcancer
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
FR2794371B1 (fr) * 1999-10-07 2004-06-18 Biovector Therapeutics Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination

Also Published As

Publication number Publication date
ES2312801T3 (es) 2009-03-01
DE60323634D1 (de) 2008-10-30
AU2003249143B2 (en) 2008-05-08
CN1656116A (zh) 2005-08-17
EP1509543B1 (de) 2008-09-17
ATE408620T1 (de) 2008-10-15
EP1509543A2 (de) 2005-03-02
FR2839072A1 (fr) 2003-10-31
US7314629B2 (en) 2008-01-01
AU2003249143A1 (en) 2003-11-10
JP2005532298A (ja) 2005-10-27
BR0309491A (pt) 2005-02-15
CA2483819A1 (fr) 2003-11-06
WO2003090667A2 (fr) 2003-11-06
US20060233820A1 (en) 2006-10-19
CA2483819C (fr) 2013-01-22
WO2003090667A3 (fr) 2004-04-01

Similar Documents

Publication Publication Date Title
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
JP2019013251A5 (de)
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
EA200870237A1 (ru) Последовательности пептидов и композиции
JP2018510622A5 (de)
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
NO20063026L (no) Antistoffer
ATE267211T1 (de) Impfstoff gegen hpv
NO20025153D0 (no) FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1
MY103854A (en) A recombinant marek''s disease virus and a vaccine.
RU2018105007A (ru) Композиции против аллергии на кошек
ATE287957T1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
JPWO2010074126A1 (ja) 組換え鶏伝染性コリーザワクチン及びその製造方法
DK2076532T3 (da) Cytokinderivater
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
WO2023038961A3 (en) Common cold coronavirus t cell epitopes, methods and uses thereof
NO20005081L (no) Et polypeptid som omfatter aminosyren fra et N-terminalt kolinbindende protein A trunkat, vaksine avledet derav og anvendelser derav
Kubo et al. The unblocked N-terminal sequence of chicken IgG λ-like light chains
PE20010238A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS SodC, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS
NZ570708A (en) Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
PE20010237A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS OmpH, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS
DK1005487T3 (da) Ydre 74 kD-membranprotein fra Moraxella catarrhalis
PE20010316A1 (es) GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS
PE20010239A1 (es) Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos